FDA Pooled Analysis: Survival Outcomes With First-line Chemo-IO vs IO Alone for Treatment of Advanced NSCLC With PD-L1 Expression 1% to 49%

June 4-8, 2021; Online at https://conferences.asco.org/am
Results of this retrospective exploratory analysis suggest that chemo-IO regimens may improve OS and PFS compared with IO alone in most patients with previously untreated advanced NSCLC and tumor PD-L1 expression 1% to 49%.
Format: Microsoft PowerPoint (.ppt)
File Size: 521 KB
Released: June 5, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Patient-friendly resource on immune checkpoint inhibitor therapy for early-stage NSCLC from Clinical Care Options (CCO)

Elizabeth Krueger, NP Released: September 22, 2021

Phase I trials of EGFR/HER2 inhibitor DZD9008 in patients with advanced NSCLC and EGFR ex20ins mutations, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 20, 2021

Phase II ATEZO-BRAIN evaluating atezolizumab plus carboplatin/pemetrexed in advanced NSCLC with untreated brain metastases, from WCLC2021 as reported by Clinical Care Options (CCO)

Released: September 20, 2021

Download these slides for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, from CCO

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue